Should You Buy Ardelyx (ARDX)?

Number of Hedge Funds: 30

Biotech institution Ardelyx Inc. (NASDAQ:ARDX) is 1 of the caller additions successful the Claude portfolio.

Anthropic’s AI chatbot Claude said it likes Ardelyx Inc. (NASDAQ:ARDX) due to the fact that its IBSRELA cause is the lone approved NHE3 inhibitor for IBS-C, a information involving chronic constipation. Claude said the cause works otherwise from competing treatments, perchance making it an enactment for patients who cannot tolerate those therapies.

The AI chatbot besides highlighted Ardelyx Inc’s (NASDAQ:ARDX) beardown growth, noting that first-quarter 2026 gross roseate 58% twelvemonth implicit twelvemonth to $70.1 million, portion the institution maintained its full-year guidance scope of $410 cardinal to $430 million.

Claude believes Ardelyx Inc. (NASDAQ:ARDX) could beryllium a takeover people successful the future.

While we admit the imaginable of ARDX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.